TickerTalks
Browse all tickers →
TickerTalks›$ILMN
ILILMN

Illumina, Inc.

$ILMN·$33B·Medical - Diagnostics & Research·Healthcare
$212.71-2.5%YTD+66.2%1Y+122.3%
Price updated 12m ago·X counts updated 21h ago
ILILMN
$ILMNIllumina, Inc.
$212.71-2.52%289 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $ILMN on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

289X posts · last 7 days
Aug 22Sep 7
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $ILMN's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 60% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data39 posts analyzed · as of 2026-09-07

Illumina is joining the S&P 500 effective Sept 21 alongside Bloom Energy and Everpure. The tape is one long automatic-inflows victory-lap thread; no bear voice appears. This is a passive-rebalance bullish catalyst rather than a fundamental narrative shift.

Read what X is saying about $ILMN

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ILMN — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-07

The move is getting stronger, with heavier trading behind it.

Genomics leader running into S&P 500 inclusion — mechanics stabilized, $239M of insider selling is the real caution.

Illumina is the dominant DNA-sequencing platform for research and clinical labs — a business that spent two years digesting the GRAIL saga and a genuine market-share fight from Element Biosciences and others. Now it's heading into S&P 500 inclusion on September 21.

  • The business has stabilized and margins are working: revenue up 5% YoY at $1.1B/quarter with 68% gross margins and 21% operating margins — a healthy print base after a couple of very rough years, and the reason the multiple is re-rating alongside the index bid.
  • The inclusion catalyst is real and dated: joining the S&P 500 effective September 21, replacing Builders FirstSource — YTD +66% into the event and a durable flow bid from passive funds that must buy at the close.
  • The insider signal is unusually loud: $239M of officer selling with zero open-market buys — the largest single-name insider-selling cluster in this batch, and it deserves real weight on a name at 92% of the 52-week range going into forced index buying.

A Q3 print showing continued revenue reacceleration extends the run; the $239M insider signal plus any high-throughput sequencer capacity slip is the risk to the setup, and the crowd's zero-pushback stance is not the whole story here.

Differs from X sentimentThe X read is the S&P 500 inclusion mechanics only, and the crowd is right that the flow bid is real. But the crowd's zero-pushback stance ignores $239M of insider selling with zero buys — the loudest counter-signal in the entire batch — and that's what the alignment note has to name honestly.

What to watch: Sept 21 S&P 500 inclusion, then Oct 29 earnings — revenue growth (needs above 5%), instrument-placement trend, and whether the insider selling continues after inclusion. A hot print extends the run; continued insider selling with a soft print breaks the setup at these highs.

On the calendar: 2026-09-21 — S&P 500 inclusion

Read the AI verdict on $ILMN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes DNA sequencing instruments, consumables, and arrays that underpin genomics research, oncology diagnostics, and reproductive health testing globally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $ILMN.

Medical - Diagnostics & Research · Healthcare

AI-driven diagnostic platforms (multi-cancer early detection, liquid biopsy) are the highest-growth segment; CRO demand from pharma R&D pipelines sustains contract research volume. Lab-equipment destocking has largely worked through, with instrument spend recovering.

What this means for $ILMN

Partial — Illumina sequencing; GRAIL Galleri spin-off, sequencing instrument install base dominant, multi-cancer detection commercialising.

Industry benchmark

15-name peer basket
+18.8%YTD
+49.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
33.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
21.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
34.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
67.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$1.31$1.23+6.5%
Q1 2026Apr 30, 2026$1.15$1.05+9.5%
Q4 2025Feb 5, 2026$1.35$1.24+8.9%
Q3 2025Oct 30, 2025$1.34$1.17+14.5%
Next earningsThu, Oct 29·consensus EPS $1.38

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.1B+4.8%68.2%21.3%$0.88$251.0M
Q4 FY25$1.2B+5.1%67.1%22.2%$2.18$267.0M
Q3 FY25$1.1B+0.3%67.6%21.3%$0.98$260.0M
Q2 FY25$1.1B-4.9%67.8%21.0%$1.50$211.0M

Forward consensus

5-year forecast · up to 15 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$4.6B$4.6B – $4.6B$5.35$5.33 – $5.3913
FY27$4.9B$4.8B – $5.0B$6.07$5.84 – $6.5313
FY28$5.3B$5.0B – $5.6B$7.02$6.67 – $7.7215
FY29$5.7B$5.6B – $5.9B$8.07$7.86 – $8.337
FY30$6.0B$5.9B – $6.1B$8.96$8.73 – $9.257

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.91%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+10.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+43.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 147.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.475-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 4Keith A. MeisterDirector119.5K sh$26.1MSellSep 3Keith A. MeisterDirector76.0K sh$16.6MSellSep 2Keith A. MeisterDirector68.1K sh$14.5MSellAug 27Keith A. MeisterDirector138.4K sh$31.7MSellAug 26Keith A. MeisterDirector106.5K sh$24.0MSellAug 25Keith A. MeisterDirector131.0K sh$29.5MSellAug 21Keith A. MeisterDirector75.4K sh$16.2MSellAug 20Keith A. MeisterDirector285.2K sh$61.0MSellAug 19Keith A. MeisterDirector95.0K sh$19.3MSellAug 18Wedel Christensen JakobSVP, Strategy/Corp Development1.0K sh$198K
1–10 of 23
+ 17 other (12 awards · 2 inthemoneys · 2 others · 1 inkind) in window

See when $ILMN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAgreement terminatedAug 138-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation
AI summary

Illumina, Inc. (ILMN) entered into a new $1 billion senior unsecured five-year revolving credit facility on August 13, 2026, with Bank of America as administrative agent; the facility includes a $50M swingline sublimit and a $75M letter-of-credit sublimit. The company simultaneously terminated an existing credit facility (Item 1.02) and the new arrangement is classified as creation of a direct financial obligation (Item 2.03). Illumina may expand commitments by up to an additional $500M with lender consent. The facility carries a variable rate tied to SOFR or the alternate base rate plus a spread based on debt ratings, with a maximum leverage ratio financial covenant — a standard refinancing at favorable terms for the genomics leader.

3New insider — initial holdingsAug 113
AI summary

Illumina (ILMN) filed a Form 3 initial statement of beneficial ownership for its Chief Legal Officer. The filing records the CLO's initial holdings in Illumina common stock as required upon appointment.

3New insider — initial holdingsJul 293
AI summary

An insider (Amount or Number of Shares Explanation of Responses: No secur) at ILMN (ILMN) filed a Form 3 on 2026-07-29 reporting initial or updated beneficial ownership. This is a routine insider reporting disclosure required within 10 days of becoming a 10%+ holder or new officer/director. It has limited standalone market impact but establishes the baseline for tracking future insider transactions.

3New insider — initial holdingsJun 233
AI summary

Daniel Skovronsky, MD/PhD (director, San Diego) filed a Form 3 initial beneficial ownership statement for Illumina as of June 16, 2026. Administrative disclosure.

8-KOfficer or director changeJun 238-K — Item 5.02: Officer or director change
AI summary

Illumina's Board expanded from 9 to 10 members and appointed Daniel Skovronsky, MD/PhD as an independent director effective June 16, 2026, with no third-party arrangement and no related transactions. Addition of a scientifically credentialed independent director.

8-KShareholder voteMay 268-K — Item 5.07: Shareholder vote
AI summary

Illumina's 2026 Annual Meeting on May 21, 2026 elected all 9 director nominees for one-year terms (Caroline Dorsa, Scott Gottlieb, David King, Keith Meister, Anna Richo, Philip Schiller, Susan Siegel, Jacob Thaysen, Scott Ullem), ratified Ernst and Young as independent auditor, and approved the advisory NEO compensation vote. Routine annual meeting; all nominees elected and auditor ratified.

3New insider — initial holdingsMay 223
AI summary

David P. King (director, San Diego CA) filed a Form 3 initial beneficial ownership statement for Illumina as of May 21, 2026. Administrative disclosure for newly reporting Illumina director.

8-KOfficer or director changeApr 28-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 14 other (3 routine 8-Ks · 3 13Gs · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Illumina (ILMN) Upgraded to Buy: What Does It Mean for the Stock?zacks.com·1d agoBloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600prnewswire.com·4d agoBloom Energy, Illumina, Everpure Rise On S&P 500 Inclusioninvestors.com·4d agoAre Robots the New Normal? Bet on these ETFs to Invest in the Futurezacks.com·4d agoThe Market Just Told You Which Layer Of AI Biology It Is Paying Forglobenewswire.com·5d ago

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$GH$NTRA$TMO$PSNL$DHR$BLLN
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport